Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Although immunotherapy such as immune checkpoint inhibitors has shown promising
efficacy in cancer treatment, the responsiveness among patients is relatively limited …

Single-cell RNA-sequencing (scRNA-seq) presents better insights into cell behavior in the
context of a complex tumor microenvironment by profiling single-cell populations. However …

Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …

There is considerable potential for integrating transarterial chemoembolization (TACE),
programmed death-(ligand) 1 (PD-[L] 1) inhibitors, and molecular targeted treatments (MTT) …

Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …

Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Background Personalized immunotherapy utilizing cancer vaccines tailored to the tumors of
individual patients holds promise for tumors with high genetic heterogeneity, potentially …